Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Topline data presented from phase II INTERACT study of luvadaxistat

March 3, 2021

Tetracyclines curb neuropathic pain

March 3, 2021

ADORA2A is a therapeutic target in progressive multiple sclerosis

March 2, 2021

FDA clears IND application for FX-301 for postoperative pain

March 2, 2021

Alkermes patents mu-opioid receptor agonists

March 2, 2021

Enrollment opens in phase II study of RO-7017773 for autism spectrum disorder

March 2, 2021

NLY-01 exerts neuroprotective effects in model of experimental autoimmune encephalomyelitis

March 2, 2021

First-in-human data for ACT-1004-1239

March 2, 2021

Enrollment ongoing in phase I/II study of SPL-026

March 1, 2021

FDA grants accelerated approval to Amondys 45 for Duchenne muscular dystrophy

Feb. 26, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 20, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...